The Journal of Urology Vol. 196 (2016): November

The Journal of Urology® Home Study Course is a comprehensive learning activity developed by a team of educators, academicians and clinicians.

Target Audience

This course is designed for:

  • Practicing Urologists
  • American Board of Urology (ABU) candidates
  • Residents

Learning Objectives

After completing each lesson, the participants should be able to:

  1. Assess their knowledge of urology
  2. Demonstrate an increased knowledge base of urology
  3. Apply the increased knowledge to improve quality of patient care
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
11/01/2016
Course expires: 
11/30/2019
Rating: 
0

Disclosures

(Individuals in control of the content. All individuals with their respective disclosures listed in this document are planners. Individual authors’ disclosures are located with their articles in each issue of The Journal of Urology®.)

Planner Disclosures

Victor Nitti, MD: Astellas: Health Publishing, Scientific Study or Trial; Allergan: Health Publishing, Scientific Study or Trial; Serenity Pharmeuticals: Investment Interest; Cook Myosite: Scientific Study or Trial

Tracey Krupski, MD: Argos: Scientific Study or Trial; NCI-RAZOR: Scientific Study or Trial

The Journal of Urology® Editorial Board

Karl-Erik Andersson, M.D., Ph.D.: Astellas, Allergan: Consultant or Advisor, Meeting Participant or Lecturer; Ferring: Consultant or Advisor, Meeting Participant or Lecturer

Daniel Ari Barocas, M.D.: Janssen: Consultant or Advisor; Tolmar: Consultant or Advisor

Laurence Seth Baskin MD: Nothing to disclose

Peter Colin Black, M.D.: GenomeDx Biosciences Inc: Consultant or Advisor, Scientific Study or Trial; Janssen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Astellas: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Amgen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Sitka: Consultant or Advisor; Ferring: Consultant or Advisor, Meeting Participant or Lecturer; AbbVie: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; RedLeaf Medical: Meeting Participant or Lecturer; Novartis: Meeting Participant or Lecturer; Biocancell: Consultant or Advisor; Cubist: Consultant or Advisor; Roche/Genentech: Scientific Study or Trial; World Journal of Urology: Health Publishing; Urologic Oncology: Health Publishing; Bladder Cancer: Health Publishing; PLOS ONE: Health Publishing; BMC Urology: Health Publishing

Robert Edward Brannigan MD: The American Society for Reproductive Medicine (ASRM): Leadership Position, Health Publishing; The American Society for Reproductive Medicine: Leadership Position; AbbVie, Inc.: Other; The National Institutes of Health: Other

Toby C. Chai, MD: Ion Channel, Inc.: Consultant or Advisor; Allergan: Consultant or Advisor

Peter Earl Clark, M.D.: Galil Medical: Consultant or Advisor; Genentech: Consultant or Advisor

Craig Vance Comiter, M.D.: coloplast: Consultant or Advisor; axiom: Consultant or Advisor; Nine Continents Medical, Inc: Consultant or Advisor; Revance: Scientific Study or Trial

Tracy M. Downs, M.D.: Nothing to disclose

Scott E. Eggener, M.D.: Janssen Pharmaceuticals: Consultant or Advisor, Meeting Participant or Lecturer; Myriad Genetics: Consultant or Advisor, Scientific Study or Trial; NxThera: Consultant or Advisor; Profound Medical: Consultant or Advisor; Genomic Health: Consultant or Advisor, Scientific Study or Trial; MDx Health: Consultant or Advisor, Meeting Participant or Lecturer

Brian Howard Eisner, MD: Ravine Group: Owner, Product Development; Gyrus/ACMI/Olympus: Consultant or Advisor; Boston Scientific: Consultant or Advisor; Bard: Consultant or Advisor; Retrophin: Consultant or Advisor

Howard B. Goldman, MD: allergan: Meeting Participant or Lecturer; astellas: Meeting Participant or Lecturer; Medtronic: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; uroplasty: Consultant or Advisor, Meeting Participant or Lecturer; Wellspect: Consultant or Advisor; Cook: Scientific Study or Trial; american medical systems: Consultant or Advisor, Meeting Participant or Lecturer; Pfizer: Consultant or Advisor, Meeting Participant or Lecturer; axonics: Consultant or Advisor

E. Ann Gormley, MD: SUFU Foundation: Leadership Position

Wayne John G. Hellstrom MD: Endo: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Theralogix: Leadership Position; Coloplast: Consultant or Advisor, Meeting Participant or Lecturer; Lilly: Consultant or Advisor, Meeting Participant or Lecturer; American Medical Systems: Consultant or Advisor; NIH: Leadership Position; Antares: Consultant or Advisor; Auxilium: Consultant or Advisor, Scientific Study or Trial; New England Research Institutes, Inc: Other; Promescent: Consultant or Advisor; Abbvie: Consultant or Advisor; Pfizer: Consultant or Advisor; Astellas: Consultant or Advisor; Repros Therapuetics: Consultant or Advisor; Allergan: Consultant or Advisor; Menerini: Meeting Participant or Lecturer; Lipocine, Inc: Consultant or Advisor

Gerald H. Jordan, MD, FACS: Precision Medical Devices: Consultant or Advisor; Engineers and Doctors/Wallsten/PNN: Leadership Position, Consultant or Advisor; C&S Surgical: Other; American Board of Urology: Employee

Laurence H. Klotz, M.D.: Ferring: Consultant or Advisor, Scientific Study or Trial; Amgen: Consultant or Advisor, Scientific Study or Trial; Astellas: Meeting Participant or Lecturer, Scientific Study or Trial; Medivation: Meeting Participant or Lecturer, Scientific Study or Trial; Abbvie: Meeting Participant or Lecturer, Scientific Study or Trial; Janssen: Meeting Participant or Lecturer, Scientific Study or Trial

Badrinath R. Konety, MD: Axogen Inc.: Consultant or Advisor; Photocure Inc: Scientific Study or Trial; Myriad Genetics: Scientific Study or Trial; Genomic Health: Scientific Study or Trial; Takeda Inc: Consultant or Advisor

John N. Krieger, MD: Pfizer: Consultant or Advisor, Scientific Study or Trial

Jaime Landman, MD: Cook Urological: Consultant or Advisor, Owner, Product Development; Cook: Consultant or Advisor; Galil Medical: Consultant or Advisor; SurgiQuest: Leadership Position, Consultant or Advisor, Scientific Study or Trial, Investment Interest; Aesculap: Scientific Study or Trial

Gary Evan Lemack, M.D.: Astellas: Meeting Participant or Lecturer; Pfizer: Investment Interest; Allergan: Meeting Participant or Lecturer; Sophiris: Scientific Study or Trial; Medtronic: Consultant or Advisor

Yair Lotan, M.D.: abbott: Scientific Study or Trial; Danone: Consultant or Advisor, Scientific Study or Trial; Cepheid: Scientific Study or Trial; Pacific Edge: Scientific Study or Trial; FKD: Scientific Study or Trial; MDxHealth: Consultant or Advisor; biocancell: Scientific Study or Trial; Genomic Health: Scientific Study or Trial; GenomeDx Biosciences Inc: Scientific Study or Trial; photocure: Scientific Study or Trial

William Thomas Lowrance, M.D.: Myriad Genetics: Scientific Study or Trial; Genome Dx: Scientific Study or Trial; Argos: Scientific Study or Trial

Kevin Thomas McVary ,MD, FACS: Astellas: Scientific Study or Trial; Lilly/ICOS: Consultant or Advisor, Scientific Study or Trial; NIDDK: Scientific Study or Trial; AMS: Scientific Study or Trial; Sophris: Scientific Study or Trial

Maxwell V. Meng, M.D.: Nothing to disclose

Nicole Lara Miller, M.D.: Lumenis: Meeting Participant or Lecturer

Ajay Nehra, M.D.: International Society of Mens Health: Leadership Position; American Society of Mens Health: Leadership Position; AUA NEWS: Leadership Position; Journal of Mens Health: Leadership Position; Sexual Medicine Society of North America: Leadership Position; ICUD: Meeting Participant or Lecturer; ICUD: Meeting Participant or Lecturer; Journal of Urology: Health Publishing

Joel Byron Nelson, MD: ImaginAb: Consultant or Advisor

Mike Minh Nguyen, M.D., MPH: Nothing to disclose

Craig Stuart Niederberger, M.D.: AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE: Leadership Position, Meeting Participant or Lecturer; NexHand: Leadership Position, Investment Interest, Owner, Product Development; Ferring Pharmaceuticals: Scientific Study or Trial

John Luther Phillips, MD: Nothing to disclose

Mrs. Deborah F. Polly (STAFFLIAISON): Nothing to disclose

Arthur I. Sagalowsky, M.D.: Journal of Urology: Health Publishing; Urologic Oncology: Health Publishing; Current Urology Reports: Health Publishing; Bladder Cancer Advocacy Network: Leadership Position; American Urological Association: Meeting Participant or Lecturer; South Central Section of American Urological Association: Leadership Position

Bradley Fields Schwartz, M.D.: Cook Medical: Meeting Participant or Lecturer

Ojas Shah, M.D.: Boston Scientific: Consultant or Advisor, Meeting Participant or Lecturer; NJ Kidney Stone Center: Investment Interest; MD Agree: Consultant or Advisor, Investment Interest

Joseph A. Smith Jr., M.D. (JUEDITOR): Nothing to disclose

John Arthur Taylor III, M.D.: Nothing to disclose

Ramakrishna Venkatesh, MD: Nothing to disclose

Julian Hsin-Cheng Wan, MD: Allergan: Scientific Study or Trial

Accreditation

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American Urological Association designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

AUA Disclosure Policy

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/ or Education Content Review Committee or its subgroup
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point- counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Evidence-based Content

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

Off label or Unapproved Use of Drugs or Devices

It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer

The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Copyright © 2016 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.